The novel adjuvant CoVaccineHT™ increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro

This publication has 28 references indexed in Scilit:

• Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial
  The Journal of Infectious Diseases, 2008
• Induction of cytotoxic T‐lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin
  Immunology, 2008
• Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant
  Clinical and Experimental Immunology, 2007
• TLR signaling
  Cell Death & Differentiation, 2006
• Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy
  The Journal of Infectious Diseases, 2005
• Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition
  Vaccine, 2004
• Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments
  Virus Research, 2004
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
  The Lancet, 2001
• Cross‐protection and cross‐reactive cytotoxic T cells induced by influenza virus vaccines in mice
  European Journal of Immunology, 1980
• The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
  Epidemiology and Infection, 1972